06887 东阳光药 通函：致非登记股东之通知信函及回条 – 以电子方式发布公司通讯之安排
SUNSHINE LAKE PHARMA CO., LTD.
广东阳光药业股份有限公司
(A joint stock company incorporated in the People’s Republic of China with limited liability)
（于中华人民共和国注册成立的股份有限公司）
(Stock Code股份代号: 6887)
18 August 2025
Dear non-registered shareholder(s),
Arangement of Electronic Disemination of Corporate Comunications
Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) under the expansion
of paperles listing regime and electronic disemination of corporate comunications that came into efect on 31 December 2023, Sunshine Lake Pharma Co., Ltd. (the “Company”) is
writing to inform you that the Company has adopted electronic disemination of corporate comunications (the “Corporate Comunication”), which mean any documents isued or to
be isued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its anual acounts together with a copy of
the auditors’ report and, where aplicable, its sumary financial report; (b) the interim report and, where aplicable, its sumary interim report; (c) a notice of meting; (d) a listing
document; (e) a circular; and (f) a proxy form.
Please note that both the English and Chinese versions of al future Corporate Comunications wil be available electronicaly on the websites of the Company at w.hecpharm.com and
the Stock Exchange at w.hkexnews.hk in place of printed copies. You should proactively aces the websites of the Company and the Stock Exchange to kep track of the release of
Corporate Comunications.
You should liaise with your bank(s), broker(s), custodian(s), nomine(s) or HKSC Nomines Limited (colectively, the “Intermediaries”) through which your shares of the
Company are held and provide your email adres to your Intermediaries.
If you want to receive the Corporate Comunications in printed form, please complete and return the Reply Form on the reverse side herein to the Company’s Hong Kong share registrar
(the “Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Flor, Hopewel Centre, 183 Quen’s Road East, Wan Chai, Hong Kong or send an email to
hecpharmaIR@hec.cn specifying your name, adres and request to receive the Corporate Comunications in printed form.
Should you have any queries relating to this leter, please contact the Company at +86-769-88615888-2051 during busines hours from 9:00 a.m. to 12:00 p.m. and from 2:00 p.m. to
5:00p.m. (Hong Kong time), Monday to Friday, excluding public holidays in Hong Kong and Mainland China.
各位非登记股东：
以电子方式发布公司通讯之安排
根据自2023年12月31日起生效的扩大无纸化上市机制及以电子方式发布公司通讯规定下香港联合交易所有限公司（「联交所」）证券上市规则（「上市规则」）第2.07A
条，广东阳光药业股份有限公司（「公司」）谨此通知 阁下，公司已采用以电子方式发布公司通讯（「公司通讯」）之安排，该公司通讯是指公司为向其任何证券持有
人提供资讯或提醒其采取行动而发布或将要发布的任何文件，包括但不限于(a) 董事报告、年度帐目以及审计报告副本以及（如适用）财务摘要报告； (b) 中期报告及其中
期报告摘要（如适用）； (c) 会议通知； (d) 上市文件； (e) 通函；和 (f) 委任表格。
请注意，所有未来公司通讯的英文版和中文版将在公司网站w.hecpharm.com和联交所网站w.hkexnews.hk上提供，以代替印刷本。 阁下应主动查看公司网站和披露
易网站以留意公司通讯的发布。
阁下应联络代 阁下持有公司股份的银行、经纪、托管商、代理人或香港中央结算（代理人）有限公司（统称「中介公司」），并向 阁下的中介公司提供 阁下的电子
邮件地址。
若 阁下希望收取公司通讯之印刷版，请填妥本函背页之回条并交回公司的香港股份过户登记处（「股份过户处」）香港中央证券登记有限公司，地址为香港湾仔皇后大道
东 183 号合和中心17M 楼或发送电子邮件至hecpharmaIR@hec.cn，并注明 阁下的姓名、地址以及收取公司通讯印刷版的要求。
如 阁下对本函件有任何疑问，请于办公时间星期一至五（香港及中国大陆公众假期除外）上午9时正至12时正以及下午2时正至5时正（香港时间）期间致电+86-769-
88615888-2051联络公司查询。
2025年8月18日
Yours faithfuly
On behalf of the Board
Sunshine Lake Pharma Co., Ltd.
ZHANG Yingjun
Chairman
代表董事会
广东阳光药业股份有限公司
董事长
张英俊
谨启
Please cut the mailing label and stick it on an envelope to return this form to us.
No postage is necesary if posted in Hong Kong.
当 阁下寄回此回条时，请将邮寄标签剪贴于信封上。
如在本港投寄， 阁下无需支付邮费或贴上邮票。
CS3050 SLPH_NRH
REPLY FORM 回条
To: Computershare Hong Kong Investor Services Limited (the “Share Registrar”) 致： 香港中央证券登记有限公司 （「股份过户处」）
17M Flor, Hopewel Centre 香港湾仔皇后大道东183号
183 Quen’s Road East, Wanchai, Hong Kong 合和中心17M楼
REMINDER 提示
As a non-registered shareholder, you should liaise with your bank(s), broker(s), custodian(s), nomine(s) or HKSC Nomines Limited
(colectively, the “Intermediaries”) through which your shares are held and provide your email adres to your Intermediaries.
作为非登记股东， 阁下应联络代 阁下持有股份的银行、经纪、托管商、代理人或香港中央结算（代理人）有限公司（统称「中介公
司」），并向 阁下的中介公司提供 阁下的电子邮件地址。
Request for Corporate Comunications
*
in printed form / 要求收取公司通讯
*
印刷版
(Please mark “✓” in the below box if aplicable)（如适用，请在以下方格内划上「✓」号）
Name of the listed company (the “Company”): SUNSHINE LAKE PHARMA CO., LTD.
上市公司（「公司」）名称： 广东阳光药业股份有限公司
I/we would like to receive future Corporate Comunications* in printed form.
本人 ╱ 我们欲收取未来公司通讯
*
的印刷版。
Printed English version 英文印刷本 Printed Chinese version 中文印刷本 Printed English and Chinese versions 中、英文印刷本
Name(s) of non-registered holder(s):
非登记股东姓名：
Signature(s):
签名：
(Please use BLOCK LETERS 请用正楷填写)
Contact number:
联络电话号码：
Date:
日期：
Notes:
附注：
1. This leter is adresed to non-registered holder(s) (“Non-registered holder” means such person or company whose shares are held in The Central Clearing and Setlement System (CAS) and who has notified the Company
from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Comunications*).
函件乃向本公司之非登记股东（「非登记股东」指股份存放于中央结算及交收系统的人士或公司，已透过香港中央结算有限公司不时向本公司发出通知，表示欲收取公司通讯
*
）发出。
2. Please complete al your details clearly.
请 阁下清楚填妥所有资料。
3. Any form with no box marked “
✓
”, with no signature or otherwise incorectly completed wil be void.
任何回条未有在方格内划上「
✓
」号、或未有签署、或在其他方面填写不正确，则将会作废。
4. For the avoidance of doubt, the Company does not acept any other instructions given on this Reply Form.
为免存疑，在本回条上的任何额外指示，公司将不予处理。
- , Corporate Comunications refer to any documents isued or to be isued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’
report, its anual acounts together with a copy of the auditors’ report and, where aplicable, its sumary financial report; (b) the interim report and, where aplicable, its sumary interim report; (c) a notice of meting; (d)
a listing document; (e) a circular; and (f) a proxy form.
除非另有注明，公司通讯乃指公司已发出或将予发出以供其任何证券的持有人参照或采取行动的任何文件，其中包括但不限于(a) 董事报告、年度帐目以及审计报告副本以及财务摘要报告（如适用）； (b) 中期报告其
中期报告摘要（如适用）； (c) 会议通知； (d) 上市文件； (e) 通函；和 (f) 委任表格。
PERSONAL INFORMATION COLECTION STATEMENT
收集个人资料声明
(i) “Personal Data” in this statement has the same meaning as “personal data” in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong (the “PDPO”).
本声明中所指的「个人资料」与香港法例第486章《个人资料（私隐）条例》（「《私隐条例》」）中「个人资料」的涵义相同。
(i) Your Personal Data provided in this Reply Form wil be used in conection with the Company’s electronic disemination of Corporate Comunications*. Your suply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide suficient information,
the Company may not be able to proces your instructions and/or requests as stated in this Reply Form.
阁下于本回条所提供的个人资料将用于有关公司以电子方式发布公司通讯*的事宜上。 阁下是自愿向本公司提供个人资料。若 阁下未能提供足够资料，本公司可能无法处理 阁下在本回条上所述的指示及/或要求。
(i) Your Personal Data may be disclosed or transfered by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and wil be retained for such period as may be necesary for our
verification and record purposes.
公司可就任何所说明的用途或在法例规定的情况下，将 阁下的个人资料披露或转移给公司的附属公司、股份过户处、及/或其他公司或团体，并将在适当期间保留该等个人资料作核实及纪录用途。
(iv) You have the right to request aces to and/or corection of your Personal Data in acordance with the provisions of the PDPO. Any such request for aces to and/or corection of your Personal Data should be in writing, by mail to the Hong Kong Privacy Oficer of the Share
Registrar at 17M Flor, Hopewel Centre, 183 Quen’s Road East, Wanchai, Hong Kong or by email at PrivacyOficer@computershare.com.hk.
阁下有权根据《私隐条例》的条文查阅及/或修改 阁下的个人资料。任何该等查阅及/或修改个人资料的要求均须以书面方式邮寄至股份过户处（地址为香港湾仔皇后大道东183号合和中心17M楼）向香港隐私主任提出，或发送电邮至
PrivacyOficer@computershare.com.hk。
Mailing Label 邮寄标签
Computershare Hong Kong Investor Services
Frepost No.
Hong Kong